AMPH Q2 2024 Earnings — Amphastar Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMPHAmphastar Pharmaceuticals, Inc.

$894M

Q2 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$182M+25.2% YoY

Gross Profit

$95M52.2% margin

Operating Income

$55M30.3% margin

Net Income

$38M20.8% margin

EPS (Diluted)

$0.73

QoQ Revenue Growth

+6.1%

Cash Flow

Operating Cash Flow

$69M

Free Cash Flow

$63M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$1.5B

Total Liabilities

$778M

Stockholders' Equity

$713M

Cash & Equivalents

$190M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$182M	$146M	+25.2%
Gross Profit	$95M	$73M	+30.8%
Operating Income	$55M	$37M	+49.7%
Net Income	$38M	$26M	+45.3%

Revenue Segments

Product revenues, net

$179M98%

Other revenues

$3M2%

Geographic Segments

UNITED STATES

$176M97%

FRANCE

$4M2%

CHINA

$2M1%